Next Article in Journal
D-Cysteine Activates Chaperone-Mediated Autophagy in Cerebellar Purkinje Cells via the Generation of Hydrogen Sulfide and Nrf2 Activation
Next Article in Special Issue
Possible Role of Insulin-Degrading Enzyme in the Physiopathology of Retinitis Pigmentosa
Previous Article in Journal
Raman Spectroscopy as a Neuromonitoring Tool in Traumatic Brain Injury: A Systematic Review and Clinical Perspectives
Previous Article in Special Issue
Evolutionary Origin of Insulin-Degrading Enzyme and Its Subcellular Localization and Secretion Mechanism: A Study in Microglial Cells

Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?

INSERM U1177 Drugs and Molecules for Living Systems, Institut Pasteur de Lille, European Genomic Institute for Diabetes, University of Lille, F-59000 Lille, France
Author to whom correspondence should be addressed.
Academic Editors: Irene Cozar-Castellano and German Perdomo
Cells 2022, 11(7), 1228;
Received: 14 February 2022 / Revised: 31 March 2022 / Accepted: 1 April 2022 / Published: 5 April 2022
(This article belongs to the Special Issue Insulin-Degrading Enzyme in Health and Disease)
Insulin-degrading enzyme (IDE) is a multifunctional protease due to the variety of its substrates, its various cellular locations, its conservation between species and its many non-proteolytic functions. Numerous studies have successfully demonstrated its implication in two main therapeutic areas: metabolic and neuronal diseases. In recent years, several reports have underlined the overexpression of this enzyme in different cancers. Still, the exact role of IDE in the physiopathology of cancer remains to be elucidated. Known as the main enzyme responsible for the degradation of insulin, an essential growth factor for healthy cells and cancer cells, IDE has also been shown to behave like a chaperone and interact with the proteasome. The pharmacological modulation of IDE (siRNA, chemical compounds, etc.) has demonstrated interesting results in cancer models. All these results point towards IDE as a potential target in cancer. In this review, we will discuss evidence of links between IDE and cancer development or resistance, IDE’s functions, catalytic or non-catalytic, in the context of cell proliferation, cancer development and the impact of the pharmacomodulation of IDE via cancer therapeutics. View Full-Text
Keywords: insulin-degrading enzyme; cancer; target insulin-degrading enzyme; cancer; target
Show Figures

Figure 1

MDPI and ACS Style

Lesire, L.; Leroux, F.; Deprez-Poulain, R.; Deprez, B. Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer? Cells 2022, 11, 1228.

AMA Style

Lesire L, Leroux F, Deprez-Poulain R, Deprez B. Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer? Cells. 2022; 11(7):1228.

Chicago/Turabian Style

Lesire, Laetitia, Florence Leroux, Rebecca Deprez-Poulain, and Benoit Deprez. 2022. "Insulin-Degrading Enzyme, an Under-Estimated Potential Target to Treat Cancer?" Cells 11, no. 7: 1228.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop